Published in Gut on October 29, 2010
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med (2012) 7.47
Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst (2013) 4.37
Cancer immunology--analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol (2011) 2.90
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Colorectal cancer: a tale of two sides or a continuum? Gut (2012) 2.85
Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res (2012) 2.52
Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res (2012) 2.50
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res (2011) 2.40
Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA (2011) 2.28
Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA (2013) 2.26
Interdisciplinary education to integrate pathology and epidemiology: towards molecular and population-level health science. Am J Epidemiol (2012) 2.07
Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res (2012) 1.95
Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol (2013) 1.95
Review Article: The Role of Molecular Pathological Epidemiology in the Study of Neoplastic and Non-neoplastic Diseases in the Era of Precision Medicine. Epidemiology (2016) 1.89
How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn (2012) 1.66
Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. J Natl Cancer Inst (2013) 1.63
CpG island methylation in colorectal cancer: past, present and future. Patholog Res Int (2011) 1.62
Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. Mol Cancer (2014) 1.46
Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. Prog Lipid Res (2013) 1.46
Genomic aberrations occurring in subsets of serrated colorectal lesions but not conventional adenomas. Cancer Res (2013) 1.42
Marine ω-3 Polyunsaturated Fatty Acid Intake and Risk of Colorectal Cancer Characterized by Tumor-Infiltrating T Cells. JAMA Oncol (2016) 1.41
Epidemiological transition of colorectal cancer in developing countries: environmental factors, molecular pathways, and opportunities for prevention. World J Gastroenterol (2014) 1.35
The most important questions in cancer research and clinical oncology-Question 2-5. Obesity-related cancers: more questions than answers. Chin J Cancer (2017) 1.33
Body size, physical activity and risk of colorectal cancer with or without the CpG island methylator phenotype (CIMP). PLoS One (2011) 1.32
Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location. Br J Cancer (2013) 1.28
Aspirin as adjuvant therapy for colorectal cancer--reinterpreting paradigms. Nat Rev Clin Oncol (2012) 1.26
Prospective study of family history and colorectal cancer risk by tumor LINE-1 methylation level. J Natl Cancer Inst (2012) 1.24
Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene (2013) 1.23
Body mass index and risk of colorectal cancer according to fatty acid synthase expression in the nurses' health study. J Natl Cancer Inst (2012) 1.19
Serrated polyps of the large intestine: current understanding of diagnosis, pathogenesis, and clinical management. J Gastroenterol (2012) 1.18
Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status. Gut (2015) 1.17
Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut (2015) 1.17
Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. Mod Pathol (2014) 1.16
Molecular pathological epidemiology gives clues to paradoxical findings. Eur J Epidemiol (2015) 1.16
Tumor TP53 expression status, body mass index and prognosis in colorectal cancer. Int J Cancer (2011) 1.12
Promoter hypermethylation of tumour suppressor genes as potential biomarkers in colorectal cancer. Int J Mol Sci (2015) 1.09
A prospective study of duration of smoking cessation and colorectal cancer risk by epigenetics-related tumor classification. Am J Epidemiol (2013) 1.08
Molecular events in primary and metastatic colorectal carcinoma: a review. Patholog Res Int (2012) 1.07
Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. Eur J Cancer (2012) 1.07
Colorectal cancer. Nat Rev Dis Prim (2015) 1.07
Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with β-catenin (CTNNB1) status. Cancer Res (2013) 1.06
Family history of colorectal cancer in BRAF p.V600E-mutated colorectal cancer cases. Cancer Epidemiol Biomarkers Prev (2013) 1.05
Nutrients, foods, and colorectal cancer prevention. Gastroenterology (2015) 1.04
World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonisation Project: IV. Tissue collection, processing, and storage in endometriosis research. Fertil Steril (2014) 1.03
Prognostic significance and molecular features of signet-ring cell and mucinous components in colorectal carcinoma. Ann Surg Oncol (2014) 1.02
Statistical methods for studying disease subtype heterogeneity. Stat Med (2015) 1.01
B vitamins, methionine and alcohol intake and risk of colon cancer in relation to BRAF mutation and CpG island methylator phenotype (CIMP). PLoS One (2011) 1.01
Systematic review: diet-gene interactions and the risk of colorectal cancer. Aliment Pharmacol Ther (2012) 1.01
Tumor LINE-1 methylation level and microsatellite instability in relation to colorectal cancer prognosis. J Natl Cancer Inst (2014) 1.00
A nationwide Danish cohort study challenging the categorisation into right-sided and left-sided colon cancer. BMJ Open (2013) 1.00
Biomarker use in colorectal cancer therapy. J Natl Compr Canc Netw (2011) 0.99
Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions. Am J Gastroenterol (2014) 0.98
Commentary: Lifestyle factors and colorectal cancer microsatellite instability--molecular pathological epidemiology science, based on unique tumour principle. Int J Epidemiol (2012) 0.98
Genetic architecture of colorectal cancer. Gut (2015) 0.97
Predictors of lymph node count in colorectal cancer resections: data from US nationwide prospective cohort studies. Arch Surg (2012) 0.97
Survival Benefit of Exercise Differs by Tumor IRS1 Expression Status in Colorectal Cancer. Ann Surg Oncol (2015) 0.96
Expression profiling of archival tumors for long-term health studies. Clin Cancer Res (2012) 0.96
Physical activity, tumor PTGS2 expression, and survival in patients with colorectal cancer. Cancer Epidemiol Biomarkers Prev (2013) 0.96
Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies. Cancer Prev Res (Phila) (2011) 0.95
Association between body mass index and mortality for colorectal cancer survivors: overall and by tumor molecular phenotype. Cancer Epidemiol Biomarkers Prev (2015) 0.95
Integration of molecular pathology, epidemiology and social science for global precision medicine. Expert Rev Mol Diagn (2015) 0.94
Proceedings of the second international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control (2015) 0.94
No evidence for interference of h&e staining in DNA testing: usefulness of DNA extraction from H&E-stained archival tissue sections. Am J Clin Pathol (2012) 0.93
Postmenopausal hormone therapy and colorectal cancer risk in relation to somatic KRAS mutation status among older women. Cancer Epidemiol Biomarkers Prev (2012) 0.92
Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst (2013) 0.92
Influence of pre-diagnostic cigarette smoking on colorectal cancer survival: overall and by tumour molecular phenotype. Br J Cancer (2014) 0.91
The molecular genetics of colorectal cancer. Frontline Gastroenterol (2013) 0.90
Phenotypic and tumor molecular characterization of colorectal cancer in relation to a susceptibility SMAD7 variant associated with survival. Carcinogenesis (2012) 0.90
Obesity and colorectal cancer: molecular features of adipose tissue. J Transl Med (2016) 0.90
Interaction between interleukin-10 (IL-10) polymorphisms and dietary fibre in relation to risk of colorectal cancer in a Danish case-cohort study. BMC Cancer (2012) 0.90
Prognostic value of innate and adaptive immunity in colorectal cancer. World J Gastroenterol (2013) 0.90
Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to KRAS Mutation Status. J Natl Cancer Inst (2015) 0.89
Detection and differential diagnosis of colon cancer by a cumulative analysis of promoter methylation. Nat Commun (2012) 0.89
Era of universal testing of microsatellite instability in colorectal cancer. World J Gastrointest Oncol (2013) 0.88
Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages. BMC Cancer (2015) 0.87
Estrogen receptors and their implications in colorectal carcinogenesis. Front Oncol (2015) 0.86
Potential role of gastrointestinal microbiota composition in prostate cancer risk. Infect Agent Cancer (2013) 0.86
TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers. PLoS One (2011) 0.86
Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis. J Gastroenterol (2016) 0.86
Phospholipase A2G1B polymorphisms and risk of colorectal neoplasia. Int J Mol Epidemiol Genet (2013) 0.85
A Meta-Regression Method for Studying Etiological Heterogeneity Across Disease Subtypes Classified by Multiple Biomarkers. Am J Epidemiol (2015) 0.85
MGMT and MLH1 methylation in Helicobacter pylori-infected children and adults. World J Gastroenterol (2013) 0.85
Postmenopausal hormone therapy is associated with a reduced risk of colorectal cancer lacking CDKN1A expression. Cancer Res (2012) 0.84
Challenges and opportunities in international molecular cancer prevention research: An ASPO Molecular Epidemiology and the Environment and International Cancer Prevention Interest Groups Report. Cancer Epidemiol Biomarkers Prev (2014) 0.84
Fruit, vegetables, and folate: cultivating the evidence for cancer prevention. Gastroenterology (2011) 0.83
Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut (2016) 0.83
CpG island methylator phenotype and prognosis of colorectal cancer in Northeast China. Biomed Res Int (2014) 0.82
MicroRNA MIR21 and T Cells in Colorectal Cancer. Cancer Immunol Res (2015) 0.82
Lifecourse epidemiology and molecular pathological epidemiology. Am J Prev Med (2015) 0.82
Incident urothelial cancer in the Malmö Diet and Cancer Study: cohort characteristics and further validation of ezrin as a prognostic biomarker. Diagn Pathol (2014) 0.82
Body mass index and risk of colorectal cancer according to tumor lymphocytic infiltrate. Int J Cancer (2016) 0.81
Alcohol, one-carbon nutrient intake, and risk of colorectal cancer according to tumor methylation level of IGF2 differentially methylated region. Am J Clin Nutr (2014) 0.81
Annexin A10 expression in colorectal cancers with emphasis on the serrated neoplasia pathway. World J Gastroenterol (2015) 0.81
How many diseases are colorectal cancer? Gastroenterol Res Pract (2012) 0.81
Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations. PLoS One (2015) 0.81
Characterizing the prevalence of chromosome instability in interval colorectal cancer. Neoplasia (2015) 0.81
Tumor LINE-1 methylation level and colorectal cancer location in relation to patient survival. Oncotarget (2016) 0.81
A pathway approach to evaluating the association between the CHIEF pathway and risk of colorectal cancer. Carcinogenesis (2014) 0.81
Origin, Methods, and Evolution of the Three Nurses' Health Studies. Am J Public Health (2016) 0.80
The epigenomics of cancer. Cell (2007) 30.91
Genetic alterations during colorectal-tumor development. N Engl J Med (1988) 26.82
Lessons from hereditary colorectal cancer. Cell (1996) 25.73
Epigenetics in cancer. N Engl J Med (2008) 17.36
The increasing dominance of teams in production of knowledge. Science (2007) 15.24
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet (2006) 13.63
CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A (1999) 13.02
AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell (2005) 11.19
Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med (2009) 10.01
Aspirin and the risk of colorectal cancer in women. N Engl J Med (1995) 9.59
Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst (2005) 9.38
A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med (2003) 9.18
Letting the genome out of the bottle--will we get our wish? N Engl J Med (2008) 9.10
Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med (2007) 9.04
Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res (1997) 8.88
AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature (2000) 8.35
The Nurses' Health Study: lifestyle and health among women. Nat Rev Cancer (2005) 8.19
Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA (2007) 7.93
Aspirin use and reduced risk of fatal colon cancer. N Engl J Med (1991) 7.85
Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med (2006) 7.62
Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell (1998) 7.25
The incidentalome: a threat to genomic medicine. JAMA (2006) 7.24
Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology (2007) 7.16
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med (2003) 6.99
Aspirin use and survival after diagnosis of colorectal cancer. JAMA (2009) 6.93
Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology (2005) 6.34
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut (2008) 6.26
Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med (2006) 6.15
The science of team science: overview of the field and introduction to the supplement. Am J Prev Med (2008) 6.03
Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomarkers Prev (2007) 6.00
The regulated retrotransposon transcriptome of mammalian cells. Nat Genet (2009) 5.79
Genomic surveys by methylation-sensitive SNP analysis identify sequence-dependent allele-specific DNA methylation. Nat Genet (2008) 5.66
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A (2007) 5.44
Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med (1994) 5.42
Prioritizing GWAS results: A review of statistical methods and recommendations for their application. Am J Hum Genet (2010) 5.39
Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol (2006) 5.22
Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology (2008) 5.19
Transcriptional disruption by the L1 retrotransposon and implications for mammalian transcriptomes. Nature (2004) 5.15
The EPIC Project: rationale and study design. European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol (1997) 4.73
Bioinformatics challenges for genome-wide association studies. Bioinformatics (2010) 4.45
Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. J Natl Cancer Inst (2000) 4.39
Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol (2006) 4.27
Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A (2007) 4.16
BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut (2004) 4.06
Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer (2009) 3.99
CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn (2006) 3.98
Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA (2005) 3.88
Retrotransposons regulate host genes in mouse oocytes and preimplantation embryos. Dev Cell (2004) 3.85
Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study. Ann Intern Med (1998) 3.73
CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology (2002) 3.70
Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn (2007) 3.56
A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst (2008) 3.54
A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med (2004) 3.46
Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst (2005) 3.41
A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology (2006) 3.35
Serrated polyps of the large intestine: a morphologic and molecular review of an evolving concept. Am J Clin Pathol (2005) 3.29
Molecular classification and correlates in colorectal cancer. J Mol Diagn (2007) 3.25
Folate, methionine, and alcohol intake and risk of colorectal adenoma. J Natl Cancer Inst (1993) 3.25
PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol (2009) 3.24
New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet (2009) 3.22
Primary prevention of colorectal cancer. Gastroenterology (2010) 3.20
Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer (2006) 3.19
Energy balance and colon cancer--beyond physical activity. Cancer Res (1997) 3.11
Alcohol, low-methionine--low-folate diets, and risk of colon cancer in men. J Natl Cancer Inst (1995) 3.10
Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst (2006) 3.08
Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev (2000) 3.05
Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest (2000) 3.03
Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med (2001) 2.98
A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst (1991) 2.96
Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology (2003) 2.96
Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One (2008) 2.92
A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis. Cancer Epidemiol Biomarkers Prev (2007) 2.91
Antisense promoter of human L1 retrotransposon drives transcription of adjacent cellular genes. Mol Cell Biol (2001) 2.88
LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int J Cancer (2008) 2.87
Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated protein kinase activator, 5-aminoimidazole- 4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem Biophys Res Commun (2001) 2.86
Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res (2008) 2.83
PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia (2008) 2.82
Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst (2006) 2.77
Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology (2007) 2.73
Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer (2008) 2.68
Association of family history with cancer recurrence and survival among patients with stage III colon cancer. JAMA (2008) 2.67
The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology (2006) 2.63
A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. Gastroenterology (2009) 2.56
Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am J Surg Pathol (2006) 2.55
Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst (2010) 2.38
K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis (2003) 2.38
Effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut (2005) 2.37
Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. Int J Cancer (2007) 2.36
Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst (2010) 2.35
Genetic variation in 8q24 associated with risk of colorectal cancer. Cancer Biol Ther (2007) 2.32
MLH1 -93G>A promoter polymorphism and the risk of microsatellite-unstable colorectal cancer. J Natl Cancer Inst (2007) 2.24
The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin Cancer Res (2010) 2.23
Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice. Oncogene (2007) 2.22
Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer (2003) 2.19
Obesity is an independent prognostic variable in colon cancer survivors. Clin Cancer Res (2010) 2.18
CIMP status of interval colon cancers: another piece to the puzzle. Am J Gastroenterol (2009) 2.17
Architecture of inherited susceptibility to common cancer. Nat Rev Cancer (2010) 2.14
Incomplete overlapping of biological, clinical, and environmental information in molecular epidemiological studies: a variety of causes and a cascade of consequences. J Epidemiol Community Health (2002) 2.13
Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. Proc Natl Acad Sci U S A (2005) 2.11
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol (2003) 12.24
Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr (2006) 10.95
Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med (2007) 9.04
Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med (2013) 7.72
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med (2012) 7.47
Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst (2006) 7.19
Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension (2007) 6.99
Aspirin use and survival after diagnosis of colorectal cancer. JAMA (2009) 6.93
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut (2008) 6.26
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature (2008) 6.24
Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn (2005) 6.00
Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA (2005) 5.95
Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med (2006) 5.24
Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol (2006) 5.22
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst (2009) 4.72
Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn (2006) 4.68
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol (2009) 4.54
Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med (2003) 4.40
Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst (2013) 4.37
Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol (2006) 4.27
A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. Gastroenterology (2013) 4.06
Comparison of risk factors for colon and rectal cancer. Int J Cancer (2004) 4.03
CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn (2006) 3.98
Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst (2006) 3.96
Association of nut consumption with total and cause-specific mortality. N Engl J Med (2013) 3.94
Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA (2005) 3.88
Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. Gastroenterology (2011) 3.84
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn (2007) 3.56
Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature (2012) 3.54
A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst (2008) 3.54
A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst (2004) 3.49
A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med (2004) 3.46
Methods for pooling results of epidemiologic studies: the Pooling Project of Prospective Studies of Diet and Cancer. Am J Epidemiol (2006) 3.41
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol (2012) 3.36
Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol (2008) 3.34
Patients' perceptions of quality of care for colorectal cancer by race, ethnicity, and language. J Clin Oncol (2005) 3.30
PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol (2009) 3.24
Periodontal disease, tooth loss, and cancer risk in male health professionals: a prospective cohort study. Lancet Oncol (2008) 3.23
Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst (2005) 3.22
Relation of hospital volume to colostomy rates and survival for patients with rectal cancer. J Natl Cancer Inst (2003) 3.21
Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe (2013) 3.21
Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies. Ann Intern Med (2004) 3.18
Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol (2003) 3.18
Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. J Clin Oncol (2008) 3.17
A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2006) 3.13
Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control (2004) 3.10
A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Cancer Res (2007) 3.08
Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol (2010) 3.03
Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2013) 3.03
Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst (2002) 3.03
Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence. Ann Intern Med (2003) 3.01
Low serum 25-hydroxyvitamin D at critical care initiation is associated with increased mortality. Crit Care Med (2012) 2.97
Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One (2008) 2.92
Cancer immunology--analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol (2011) 2.90
LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int J Cancer (2008) 2.87
Night-shift work and risk of colorectal cancer in the nurses' health study. J Natl Cancer Inst (2003) 2.87
Coffee consumption and prostate cancer risk and progression in the Health Professionals Follow-up Study. J Natl Cancer Inst (2011) 2.85
Colorectal cancer: a tale of two sides or a continuum? Gut (2012) 2.85
Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA (2007) 2.84
Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. Am J Prev Med (2007) 2.83
PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia (2008) 2.82
Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol (2006) 2.80
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol (2006) 2.80
A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer Discov (2011) 2.77
Dietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort studies. JAMA (2005) 2.76
Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev (2004) 2.75
Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol (2008) 2.74
Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology (2007) 2.73
Cigarette smoking and colorectal cancer incidence and mortality: systematic review and meta-analysis. Int J Cancer (2009) 2.67
Association of family history with cancer recurrence and survival among patients with stage III colon cancer. JAMA (2008) 2.67
Oral contraceptives, reproductive factors and risk of inflammatory bowel disease. Gut (2012) 2.65
Smoking and prostate cancer survival and recurrence. JAMA (2011) 2.63
A prospective study of cigarette smoking and the risk of inflammatory bowel disease in women. Am J Gastroenterol (2012) 2.63